研究单位：[1]Akeso[2]Peking university people's hospital Beijing,Beijing,China[3]Peking University Shougang hospital Beijing,Beijing,China[4]Peking University Third Hospital Beijing,Beijing,China[5]Xuanwu hospital capital medical university Beijing,Beijing,China[6]Guangdong provincial people's hospital Guangzhou,Guangdong,China[7]Nanfang Hospital Guangzhou,Guangdong,China[8]The first affiliated hospital of Zhengzhou University Zhengzhou,Henan,China[9]Jiangsu Province Hospital Nanjing,Jiangsu,China[10]Nanjing Drum Tower hospital Nanjing,Jiangsu,China[11]Zhongda Hospital Southeast University Nanjing,Jiangsu,China[12]The First Affiliated Hospital of Nanchang University Nanchang,Jiangxi,China[13]The first Bethune hospital of Jilin university Changchun,Jilin,China[14]Second hospital of Shanxi Medical university Taiyuan,Shanxi,China[15]The seventh affiliated hospital,Sun Yat-sen university Shenzhen,Shenzhen,China
研究目的：
This is a phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of AK111 in subjects with active ankylosing spondylitis.
